Gilead Sciences is a leading global biopharmaceutical company headquartered in California, renowned for its advanced research and development. The company holds a dominant position in the antiviral market, having revolutionized treatments for HIV and chronic Hepatitis C, famously turning Hepatitis C into a curable disease. Beyond antivirals, Gilead is actively expanding its portfolio into oncology, immunotherapy, and inflammatory diseases, continually seeking scientific breakthroughs to address life-threatening medical conditions worldwide.
Here are some articles to give you a basic understanding of the company:
Gilead – background and history
Below is a list of articles for the company:
-
Gilead – 2026Q1 results
Here is the summary of Gilead Sciences’ (NASDAQ: GILD) Q1 2026 financial results announced on May 7, 2026. Core Financial Performance Metric Q1 2026 Q1 2025 YoY Change Total Revenue 6.96B 6.67B 4.4% Net Income 2.02B 1.32B 53.7% GAAP Diluted EPS $1.61 $1.04 54.8% Non-GAAP Diluted EPS $2.03 $1.81 12.2% Product & Segment Breakdown Full-Year…
-
Gilead – History and Competition
The history of Gilead Sciences can be divided into four distinct phases, tracking its evolution from a focused antiviral biotech startup into a global multi-therapeutic pharmaceutical giant. Phase 1: Foundation and Early Discovery (1987-2000) Phase 2: Establishing HIV Market Dominance (2001-2010) Phase 3: The Hepatitis C Breakthrough and Revenue Peak (2011-2016) Phase 4: Diversification, Oncology,…